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Abstract
Background: Gastric cancer is one of the most common cancers affecting East Asians, and MLH1 could play a
critical role during tumorigenesis in this condition.
Methods: Samples from 236 Chinese patients suffering from gastric cancer were screened for MLH1 germline
mutations. Carrier frequencies of the mutations were compared between gastric cancer patients and 240 cancer-
free controls. Bioinformatic analysis was used to predict the effect of these mutations on protein function and
mRNA splicing.
Results: Six MLH1 sequence alterations were identified in gastric cancer patients including two promoter region
substitutions, -93G>A and -28A>G, and four missense mutations 649C>T (R217C), 655A>G (I219V), 1151T>A (V384D)
and 2101C>A (Q701K). Compared with the MLH1 2101CC genotype, the 2101CA genotype was associated with a
risk of gastric cancer (OR = 8.42, 95% CI = 1.04-68.06) in males. Furthermore, the MLH1 2101C>A mutant was
predicted by in silico analysis to affect exon splicing ability. Immunohistochemistry of one index patient carrying
the MLH1 2101C>A mutation demonstrated a loss of MLH1 protein and normal expression of MSH2 and E-
cadherin. No significant differences were demonstrated between cases and controls for the other five MLH1
variants but the data indicated an ethnic difference in the frequency of these variations between Eastern Asians
and Western populations.
Conclusions: An ethnic-specific MLH1 mutation spectrum occurred in Chinese gastric cancer patients. The MLH1
2101C>A mutation could be a marker for susceptibility to gastric cancer, particularly in males.
Background
Gastric cancer is one of the most common malignancies
worldwide and is the leading cancer in East Asian coun-
tries [1]. There are two histopathological types of gastric
cancer, differentiated and undifferentiated [2], or intestinal
and diffuse types [3]. Environmental and genetic factors
may play important roles in this condition and in order to
understand its etiology, several genes have been analyzed
but few variation genotypes have been identified. Intestinal
gastric cancers have been identified as common extracolo-
nic tumors in the hereditary nonpolyposis colorectal can-
cer (HNPCC) syndrome [1], which are often caused by
germline mutations of mismatch repair genes, predomi-
nantly MLH1 (Gene ID 4292)[4]. Several groups have
investigated the association between MLH1 mutations and
the risk of developing several cancer types including color-
ectal and lung cancer. However, mutations of MLH1 and
their association with gastric cancer are rarely studied. It is
possible that some MLH1 mutations could have an effect
on mismatch repair functions, thereby modulating the sus-
ceptibility to the condition. To clarify the significance of
MLH1 mutations in the development of gastric cancer, a
study was carried out in 236 Chinese gastric cancer
patients to achieve a full spectrum of germline MLH1
mutations. In addition, a case-control study was carried
out to investigate the association between the mutations
and gastric cancer. Furthermore, bioinformatic analysis
was used to predict the effect of these substitutions on
protein function and mRNA splicing.
Methods
Clinical samples
Gastric cancer patients with onset from January 1 to
December 31 of 2008, from the East District of China,
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investigated (178 men and 58 women, mean age 62.3 ±
9.4 years, range 30-84). A total of 240 cancer-free con-
trols were recruited (mean age 61.8 ± 10.1 years, range
26-82) (Table 1). Details regarding gastric cancer family
history, onset age and histological classification are sum-
marized in Table 1. Informed consent was obtained
from all subjects who underwent genetic testing, accord-
ing to the Ethics Committee of the Medical School of
Nanjing University.
Immunohistochemistry analysis
Immunohistochemistry (IHC) of MLH1, MSH2 and E-
cadherin was performed using formalin-fixed, paraffin-
embedded tissue sections. Tissues were stained with
MLH1 antibody [Mouse monoclonal, G168-728 diluted
1:100; Zymed Laboratories, San Francisco, CA, USA],
MSH2 antibody [Mouse monoclonal, G219-1129 diluted
1:100; Zymed] and E-cadherin antibody [Mouse monoclo-
nal, 4A2C7 diluted 1:100; Zymed], and detected by the
EnVision System (Dako, Carpinteria, CA, USA).
Mutation screening
Genomic DNA was extracted from peripheral blood leu-
kocytes using the QIAamp DNA Blood Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
instructions. Mutation screening of MLH1 exons 1-19
and neighboring intronic sequences was performed using
polymerase chain reaction (PCR) and high-resolution
melting (HRM) analysis, using a LightScanner system
(Idaho technology, Salt Lake City, UT, USA). The sam-
ples that presented abnormal profiles were sequenced on
an ABI 3130-Avant automated sequencer (Applied Bio-
systems, Foster City, CA, USA). The MLH1 promoter
region was genotyped using PCR and directly sequenced
on the ABI 3130-Avant automated sequencer. PCR con-
ditions were as follows: 95°C for 30 seconds, 52-60°C for
30 seconds, and 72°C for 40 seconds for 35 cycles,
followed by 72°C for 7 min. The PCR primers for amplifi-
cation of the MLH1 gene were as described in the litera-
ture [5] with a minor modification (Additional file 1,
Table S1).
Bioinformatic analysis of MLH1 variants
The impact of amino acid allelic variants on protein struc-
ture/function can be predicted via analysis of multiple
sequence alignments and protein 3D-structures. The Sort-
ing Intolerant from Tolerant (SIFT) algorithm was applied.
SIFT is a program that predicts the effect of amino acid
substitutions on protein function, on the basis of sequence
conservation during evolution and the nature of the amino
acids substituted in a gene of interest. SIFT scores were
calculated online http://sift.jcvi.org/. If the value is less
than 0.05, the amino acid substitution is predicted as intol-
erant, while those with a value greater than or equal to
0.05 are classified as tolerated.
Changes in exonic splicing enhancers (ESEs) due to
single base substitutions were calculated using the
Table 1 Frequency distributions of variables in gastric cancer cases and controls
Variables Cases Controls P
a
Number 236 240
Age (years) 0.997
≤ 49 19 (8.1%) 19 (7.9%)
50-59 65 (27.5%) 65 (27.1%)
60-69 94 (39.8%) 98 (40.8%)
≥ 70 58 (24.6%) 58 (24.2%)
Gender 0.915
Male 178 (75.4%) 180 (75.0%)
Female 58 (24.6%) 60 (25.0%)
Family history
Familial recurrence for gastric cancer (F)
b 6 (2.5%)
Low familial recurrence for gastric cancer (LF)
c 39 (16.5%)
Young age (< 50) of sporadic disease (Y) 16 (6.8%)
Old age (≥ 50) of sporadic disease (S) 175 (74.2%)
Tumor type (Available for 162 cases)
Poorly differentiated 64 (39.5%)
Moderately differentiated 69 (42.6%)
Well differentiated 29 (17.9%)
a Two-sided c2 test;
b Individuals with gastric cancer and two or more first-degree relatives with gastric cancer or related cancers;
c Individuals with gastric cancer and one first-degree relative with gastric cancer or related cancers.
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finder provides a score matrix based on the frequencies
of the individual nucleotides at each position of the
motif sequences specifically recognized by four SR pro-
teins: SF2/ASF, SC35, SRp40 and SRp55 [6].
Statistical analysis
c2 tests or Fisher’s exact test were used to compare the
distribution of variables between cases and controls. The
Hardy-Weinberg equilibrium (p2+2pq+q2 = 1), where p
is the frequency of the variant allele and q = 1-p, was
tested by a goodness-of-fit c2t e s tt oc o m p a r et h e
observed genotype frequencies with the expected geno-
type frequencies in cancer-free controls. Unconditional
logistical regression analysis was used to calculate odds
ratios (ORs) and their 95% confidence intervals (CIs)
adjusted by age and gender. Mantel-Haenszel c2 analysis
was used to evaluate the effect of the MLH1 2101C>A
genotype stratified by age or gender. All statistical tests
were two-sided, with a P value of 0.05 considered signif-
icant, using SPSS software (version 16).
Results
Characteristics of the study population
The study comprised 236 gastric cancer cases and 240
cancer-free controls. There were no significant differ-
ences in the distributions of age and gender between the
cases and controls (P = 0.997 and 0.915, respectively)
(Table 1). The majority of studied cases were sporadic;
approximately 20% had a family history of cancer.
Tumor type was assessed in 162 cases and more than
80% of the cases were poorly differentiated or moder-
ately differentiated adenocarcinoma (Table 1).
MLH1 variations identified in gastric cancer patients
Six variations were identified in gastric cancer patients.
Two of the variants were located in the MLH1 promoter
region: -93 G>A (rs1800734) and -28A>G; four were
missense mutations in the coding region: 649C>T
(R217C) and 655 A>G (I219V, rs1799977) in exon 8,
1151T>A (V384D) in exon 12 and 2101C>A (Q701K) in
exon 18. No frameshift or nonsense mutations were
identified (Table 2).
Table 2 MLH1 mutations detected in gastric cancer cases compared with controls
Genotypes Cases Controls P
a OR (95% CI)
b P
b
-93 G>A 0.736
GG 36 (15.3%) 42(17.5%) 1.00
GA 111 (47.0%) 114(47.5%)
AA 89 (37.7%) 84(35.0%)
GA+AA 200 (84.7%) 198(82.5%) 1.18 (0.72-1.92) 0.510
A allele 61.2% 58.8% 0.435
-28A>G 1.000
c
AA 232 (98.3%) 236 (98.3%) 1.00
AG 4 (1.7%) 4 (1.7%) 1.02 (0.25-4.14) 0.978
G allele 0.85% 0.83% 1.000
c
649C>T (R217C) 0.120
c
CC 231 (97.9%) 239 (99.6%) 1.00
CT 5(2.1%) 1 (0.4%) 5.25 (0.61-45.45) 0.132
T allele 1.1% 0.2% 0.121
c
655A>G (I219V) 0.257
AA 229 (97.0%) 228 (95.0%) 1.00
AG 7 (3.0%) 12 (5.0%) 0.58 (0.22-1.50) 0.262
G allele 1.5% 2.5% 0.262
1151T>A (V384D) 1.000
c
TT 232 (98.3%) 236 (98.3%)
TA 4 (1.7%) 4 (1.7%) 1.02 (0.25-4.15) 0.976
A allele 0.85% 0.83% 1.000
c
2101C>A (Q701K) 0.120
CC 228 (96.6%) 237 (98.8%) 1.00
CA 8 (3.4%) 3 (1.3%) 2.77 (0.73 -10.57) 0.136
A allele 1.7% 0.6% 0.122
a Two-sided c 2 test for either genotype distribution or allele frequency.
b Unconditional logistic regression adjusted by age and gender
c Fisher’s exact test
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cancer-free controls. The goodness-of-fit c2t e s tv a l u e s
for -93G>A, -28A>G, 649C>T, 655 A>G, 1151T>A and
2101C>A are 0.099, 0.017, 0.001, 0.158, 0.017 and 0.009,
respectively. The P values are all larger than 0.05.
MLH1 genotypes and risk of gastric cancer
The genotype and allele distributions of the six MLH1 var-
iations between the cases and controls are summarized in
Table 2. Unconditional logistical regression analysis
demonstrated that MLH1 2101CA was not associated with
a significantly elevated risk of gastric cancer (P = 0.136,
Table 2), but further stratified analysis by gender revealed
that the risk associated with this variant genotype was sig-
nificant in males (OR = 8.42, 95% CI = 1.04-68.06; P =
0.041). In a sub-group of subjects aged between 50 and 59
years, there were more MLH1 2101CA genotypes in the
cases (7.7%) than in control subjects (0.0%), but the differ-
ence was not significant (P = 0.069) (Table 3). A higher
frequency of MLH1 649 T allele was detected in gastric
cancer patients than in controls (1.1% and 0.2%, respec-
tively; P = 0.121). The OR for heterozygote CT was 5.25
(95% CI = 0.61-45.45), but the difference was not signifi-
cant (P = 0.132) (Table 2). No difference was demon-
strated between the cases and controls for the two variants
in the promoter region, -93 G>A and -28A>G, separated
or combined (Table 2 and 4). No significant differences
existed between the cases and controls for the remaining
variations detected (Table 2).
Prediction of MLH1 protein activity and structure
The SIFT score for the MLH1 variants demonstrated that
the R217C and V384D are sorted as intolerant, suggesting
that these amino acid substitutions are predicted to
damage protein function. The remaining two variants of
MLH1, I219V and Q701K, are sorted as tolerant (Table 5).
Prediction of exon splicing
The 2101C>A variant is located at an exon-intron bound-
ary. ESEfinder predicted that the 2101C>A alteration
reduced the positive score obtained for one SF2/ASF
(2.68) to below the threshold, while it increased another
SF2/ASF motif (2.10/3.09). It produced a new positive
score for SRp40 (3.68) but decreased another SR protein,
SC35 motif (3.97/3.59).
Protein expression analysis
The MLH1 2101C>A mutation was identified in eight
patients. Carcinoma of one mutation carrier (individual
G150) was available for IHC testing, and showed loss of
M L H 1p r o t e i ne x p r e s s i o nw i t ha na b s e n c eo fd e t e c t a b l e
nuclear staining. The MSH2 protein was normally
expressed in the same tumor with normal positive nuclear
staining. IHC of E-cadherin also showed positive staining
(normal membrane staining of tumor cells) (Figure 1).
Discussion
It is widely accepted that genetic and environmental fac-
tors may be important in the etiology of gastric cancer.
Among the genetic factors, MLH1, an important gene for
DNA mismatch repair that is associated with various can-
cers, could play a role in the development of gastric can-
cer. Moreover, there might be an ethnic difference in
terms of MLH1 mutation frequency between Eastern
Asians and Western populations.
In the current study, the coding and promoter core
regions of MLH1 were studied to achieve a full spectrum
of MLH1 germline mutations in Chinese gastric cancer
patients. Six different mutations were identified including
two promoter region alterations, -93 G>A and -28A>G,
and four missense mutations, 649C>T (R217C), 655 A>G
(I219V), 1151T>A (V384D) and 2101C>A (Q701K).
The MLH1 -93 G>A single nucleotide polymorphism
(SNP) is located in the core promoter region, the 93rd
nucleotide upstream of the translation start site, and has
been described in a broad range of ethnic backgrounds.
This study revealed a frequency of 59% in control subjects
for the -93 A allele, consistent with the frequency reported
in Eastern Asians [7-9], but much higher than the 20%
prevalence reported for Europeans [10-13]. This suggests a
Table 3 Stratification analysis of gastric cancer risk associated with the MLH1 2101C>A genotype frequencies
Cases Controls OR (95%CI)
Variables CC CA CC CA CC CA P
a
Age (years)
≤ 49 19(100.0%) 0(0.0%) 19(100.0%) 0(0.0%) 1.00 - -
50-59 60(92.3%) 5(7.7%) 65(100.0%) 0(0.0%) 1.00 - 0.069
60-69 93(98.9%) 1(1.1%) 96(98.0%) 2(2.0%) 1.00 0.52(0.05-5.79) 0.971
≥ 70 56(96.6%) 2(3.4%) 57(98.3%) 1(1.7%) 1.00 2.04(0.18-23.09) 1.000
Gender
Male 170(95.5%) 8(4.5%) 179(99.4%) 1(0.6%) 1.00 8.42(1.04-68.06) 0.041
Female 58(100.0%) 0(0.0%) 58(96.7%) 2(3.3%) 1.00 - 0.493
a Mantel-Haenszel c2 test
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polymorphism. The -93 G>A SNP in MLH1 has been
implicated in the etiology of various human cancers
including breast, endometrial and ovarian cancer [8,10,12].
It is reported to have no effect on susceptibility to sporadic
colorectal cancers (CRC) [13], but when it is classified
according to MSI status, this variant is significantly asso-
ciated with an increased risk of microsatellite-unstable
CRC [11]. Furthermore, the -93 G>A polymorphism has
been shown to be associated with MLH1 methylation,
CpG island methylator positive phenotype, and BRAF
V600E mutation in microsatellite unstable CRC [14]. It is
significantly associated with the risk of lung squamous cell
carcinoma with a gene-smoking interaction [7] but not
with the risk of early-onset lung cancer [9]. In the present
study, the frequency of the -93 A allele was not signifi-
cantly different between gastric cancer cases and controls,
suggesting that this MLH1 SNP is not associated with gas-
tric cancer in our Chinese population.
The MLH1 -28A>G variation was first detected in a
Chinese female with endometrial and ovarian cancer
[15], and was reported as being present in 1/85 Chinese
colorectal cancer patients with a family history of cancer
[16]. Furthermore, its presence has been demonstrated
in Finnish prostate cancer and Portuguese HNPCC
patients [17,18]. The current study provides the first
exact frequency of the MLH1 -28A>G variation in Chi-
nese gastric cancer cases, namely 1.7% (4/236), and in
controls (4/240 (1.7%); P = 1.000). All the variation car-
riers were heterozygous for this alteration. It is possible
that one polymorphism can increase the effect of other
related polymorphisms of a gene. Therefore, the two
SNPs in the promoter region were combined to form a
series. However, no association was demonstrated
between cases and controls for the different combina-
tion of the two SNPs (Table 4).
MLH1 649C>T (R217C) was first detected in a Japa-
nese patient suffering from hereditary nonpolyposis col-
orectal cancer (HNPCC) [19]. In the current study, in
silico analysis predicted MLH1 649C>T to damage pro-
tein function. However, although a higher frequency of
MLH1 649 CT genotype was detected in gastric cancer
patients than controls (5/236 and 1/240, respectively),
the differences did not achieve significance (P = 0.120,
Table 2), which raises a question about its pathogenicity.
However, we do realize the limitation of this study due
to the relatively small sample size.
MLH1 655 A>G (I219V) has been reported as a com-
mon polymorphism in Western populations, with a G
allele frequency of more than 30% [11,20,21]. However,
in the current study it was only detected in 7 of 236
gastric cancer patients and in 12 of the 240 healthy indi-
viduals. In gastric cancer patients the G allele frequency
was 1.5%, lower than in controls who demonstrated a
frequency of 2.5%, similar to data in Eastern Asians
w h e r et h eGa l l e l ef r e q u e n c yi sr e p o r t e dt ob ea p p r o x i -
mately 2% [8,21]. This is indicative of an ethnic differ-
ence in the frequency of this polymorphism.
MLH1 1151T>A V384D has been frequently detected
in Eastern Asian HNPCC patients [15,16,22], but its
etiology in terms of cancer has not been elucidated.
This study demonstrates a comparable frequency of the
variant genotype in gastric cancer cases and controls,
suggesting that it might not be associated with gastric
cancer.
MLH1 2101 C>A (Q701K) was first identified by our
group in two Chinese gastric cancer cases [23,24] and
subsequently by Yap et al., in 2/85 Chinese HNPCC
patients [16]. Until now, this variant has not been
reported in other ethnic groups. In the current study,
MLH1 2101 C>A was detected in 8 of 236 gastric cancer
c a s e sa n di n3o ft h e2 4 0c o n t r o ls u b j e c t s .T h i sv a r i a n t
could not be associated with gastric cancer in the pre-
sent study when all individuals were analyzed together
(P = 0.120, Table 2). However, when females and males
were considered separately, 2101 CA carrier males had a
higher risk of gastric cancer than wild type individuals
(OR = 8.42, 95% CI = 1.04-68.06, P = 0.041; Table 3).
MLH1 2101 CA did not significantly influence the risk
of gastric cancer in females. This result may be a reflec-
tion on the small number of women enrolled in this
study, or it may indicate gender differences in terms of
risk. A higher frequency of MLH1 2101 CA was
detected in gastric cancer patients aged between 50 and
59 years (five out of 65; 7.7%) than in controls (0.0%).
However, it was not significantly associated with the risk
of gastric cancer (P =0 . 0 6 9 ,T a b l e3 ) ,a n do n l yat r e n d
was observed. All patients carrying this variation were
suffering from poorly or moderately differentiated
adenocarcinoma.
Table 5 MLH1 missense mutations analyzed by SIFT
Sequence variant Structural alteration SIFT scores Prediction
649C>T R217C 0.00 Intolerant
655 A>G I219V 0.57 Tolerated
1151T>A V384D 0.00 Intolerant
2101C>A Q701K 0.76 Tolerated
Table 4 Pairwise joint association for MLH1 SNPs -93 G>A
and -28A>G and gastric cancer risk
Genotype 1 Genotype 2 Cases Controls OR 95% CI P
-28A>G -93 G>A
AA GG 36 42 1.00
AG GG 0 0 - - -
AA GA or AA 196 194 1.18 0.72-1.92 0.59
AG GA or AA 4 4 1.17 0.27-5.00 0.87
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variation 2101 C>A and gastric cancer risk in males, and
this may be of biological significance. In silico analysis and
in vitro IP in this and a previous study [25] demonstrated
that this variant would not significantly affect protein
function. However, recent studies have demonstrated that
missense or silent mutations may interfere with normal
splicing [26-29]. As the variation is located in the last
amino acid in exon 18 of the MLH1 gene, in silico analysis
on splicing of pre-mRNA was performed. ESEfinder pre-
dicted that this change might influence the splicing effect
of the exon in MLH1 and therefore affect RNA transcrip-
tion and protein expression of MLH1. IHC analysis in
index patient G150 demonstrated a loss of MLH1 protein
and normal expression of MSH2 and E-cadherin (Figure
1). It could be tentatively suggested that the MLH1 2101
C>A variation might increase the risk of gastric cancer in
males. However, we cannot exclude the possibility of an
estimator bias related to the relatively small sample size
and the low frequencies of variations found. Study of a lar-
ger population and functional analysis are needed for
further evaluation of the role of this variant.
Conclusions
We have provided a full variation spectrum of the
MLH1 gene in Chinese gastric cancer patients. This data
indicates that there is an ethnic difference in terms of
MLH1 mutation frequency between Eastern Asians and
Western populations. Moreover, in this case-control
study concerning gastric cancer, it was found that the
MLH1 2101 C>A mutation may contribute to an
increased risk of gastric cancer in males.
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Additional file 1: Table S1: Primer sequences for amplification of
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